Logo OnkologischesZentrum

DKG Zusatz DAH

Liebe Patienten des Onkologischen Zentrums Dachau - Krankenhausstrasse 15 (UG Helios),

leider haben wir ein technisches Problem mit unserer Telefonanlage.
Sollten Sie die Ihnen bekannte Rufnummer 08131/ 614 920 nicht erreichen, wählen Sie bitte die folgende Nummer 08131/188 270.

Wir bitten Sie die Unannehmlichkeiten zu entschuldigen.

Ihr Praxisteam Dachau, Krankenhausstasse 15

Focus-Empfohlener-Arzt 2022

2022 Plakette Empfehlungsarzt2022 Onkologe Landkreis Donau RiesZum sechsten Mal in Folge wurde Prof. (SHB) Dr. med. Dirk Hempel im Mai 2022 mit seinen Tagesklinik in Donauwörth erneut von FOCUS-GESUNDHEIT ausgezeichnet.



RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY / BREVITY-02 in Germany)

Brief Summary: The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy


Minimum Age: 18 Years

Sex: Female

Inclusion Criteria:

  • Women aged at least 18 years;
  • Patients must be able to provide informed consent and sign the informed consent form to participate in the RDA study before any study procedures starts;
  • Newly diagnosed clinical stage I, II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal;
  • Tumour size at least 1 cm in one dimension by clinical or radiographic exam (WHO criteria);
  • Must have histological confirmation of invasive breast cancer of any subtype or grade;
  • Patient is scheduled for neoadjuvant chemotherapy +/- antibodies and +/- other drugs according to Standard of Care;
  • Patient willing to have 2 research core needle biopsies (for RDA) taken at 2 collection timepoints during neoadjuvant chemotherapy treatment.

Exclusion Criteria:

  • Patient who has had prior local (i.e. surgery or radiotherapy) or systemic (i.e. endocrine or cytotoxic) therapy for the current breast cancer;
  • Participation in another interventional clinical trial with concurrent treatment with experimental drugs;
  • Stage IV breast cancer;
  • Bilateral, multifocal or multicentric breast tumour;
  • Prior malignant disease except curatively treated basalioma of the skin or pTis of the cervix uteri;
  • Concurrent pregnancy;
  • Breast feeding woman;
  • Concurrent medical, psychiatric or addictive disorders that may limit the ability to give informed consent or complete the trial;
  • Reasons indicating risk of poor compliance with study procedures;
  • Patient not able to consent


  • Sponsor: Rna Diagnostics Inc.

Internisten • Hämatologen • Onkologen • Palliativmedizin • Onkologische Tagesklinik

Onkologische Zentren
Prof. (SHB) Dr. med. Dirk Hempel